RET and carcinoma: Vandetanib selectivity for RET was further validated in a D. melanogaster model of MEN2 syndromes and papillary thyroid carcinomas, suggesting that vandetanib can inhibit multiple RET isoforms to treat RET-dependent carcinomas (223).